Re: Jackie

[Guest guest]

Jackie, could the antibiotics they have her on also be making her that sick? I sure hope she is doing better tonight, know you all must be so exhausted.. Love, Sheena Jackie on wrote: I spoke with her a couple of min ago and she said she threw up last nite and again early this morning,, so I dont know.. Im trying to answer emails and then Im headed up there.. my mom needs me to go to the pharmacy for her too,, its always something liz,, lolelizabethnv1 <elizabethnv1earthlink (DOT) net> wrote: Hahaha I thought you'd get a kick out this . How is your daughter today ? Re: Silibinin Is a Potent Antiviral Agent in Patients with Chronic HCV Infection

Not F I N A L L Y !!!! <elizabethnv1earthlink (DOT) net> wrote: Silibinin Is a Potent Antiviral Agent in Patients with Chronic HCV Infection Not Responding to Peginterferon/Ribavirin TherapyReported by Jules LevinDDW May 21, 2008, San Diego-Matthias Scherzer, Harald Hofer, Maximilian Schoeniger-Hekele, Petra Steindl-Munda, FerenciInternal Medicine 3, Dept of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, AustriaABSTRACT from program book.Results were reported at EASL, April 2008BACKROUND: Silibinin (SIL) is the main flavonoid extracted from milk thistle (Silibum marianum G.). Without a precise knowledge of its mode

of action it can show beneficial effects in various liver diseases. Recently it was shown that SIL inhibited viral replication in the Replicon® system (Gastroenterology 2007;132:1925). In the present study we investigated the antiviral activity of SIL in patients with chronic hepatitis C who did not respond to a previous course of standard PegIFN/RBV combination therapy. METHODS: 16 nonresponder (12 male; age: 49.9±9.7 (years, mean±SD); HCV-1: n=14; HCV-4: n=2; stage of fibrosis: F3/4: n=13, F1/2: n=3; 2 pts showed a > 2 log decline of viral load at wk 12 during the preceding therapy, none had an end of treatment response) were included. Since the efficacy of oral administration is limited by its low bioavailability treatment was started with 10mg/kg Silibinin (Legalon Sil®, Madaus, Köln) infused over 4 hrs for 7 days. On day 8 treatment was changed to 140 mg Silymarin (Legalon®, Madaus, Köln) TID per os in

combination with 180µg/wk PegIFN α-2a (PEGASYS®;Roche, Basel),1-1.2 g/d ribavirin (COPEGUS®; Roche, Basel). HCV-RNA was quantified by the TaqMan® assay (Roche Diagnostics) at baseline (BL), after 7 days of SIL iv. and every 2 wks on PegINF/RBV therapy, respectively. RESULTS: On iv. SIL-monotherapy all pts showed a substantial HCV RNA decline (BL: 6.68±5.69 day 8: 0.53±0.65 MIU/ml, (mean±SD, p<0.001) with a mean log decline of 1.32±0.55 within one wk. In parallel, ALT decreased from 162±133 to 118±107 U/l (mean±SD; p=0.004). In 3 patients viral kinetics were performed and showed a linear HCV RNA decline starting at day 3. Beside mild GI symptoms iv. SIL-monotherapy was well tolerated. After initiation of PegIFN/RBV the decrease of HCV-RNA was maintained (log drop: week 2: 1.17±0.67, week 4: 1.39±0.72; week 8: 1.47±0.86; all p<0.001 vs. BL). At the time

of the meeting data amended 2 wk regimes with iv. SIL at doses of 5 mg/kg, 10mg/kg and 15 mg/kg will be available. CONCLUSION: Intravenous SIL monotherapy is well tolerated and shows a substantial antiviral effect in chronic hepatitis C patients not responding to standard combination therapy. Thus, this drug may be useful for HCV treatment, especially in nonresponders or in combination with new antivirals. The antiviral effect of high dose iv SIL was not maintained on PegIFN/RBV therapy given together with a low dose oral preparation of SIL.EASL REPORT (5-20 mg dosing)SILIBININ IS A POTENT ANTIVIRAL AGENT IN CHRONIC HEPATITIS C NOT RESPONDING TO ANTIVIRAL COMBINATION THERAPY - (05/02/08)--------------------------------------------------------------------Jackie Jackie

[Guest guest]

I dont know Sheena,, it is possible cuz this antibiotic, Levaquin is what gave BOTH my parents s s syndrome,, but the symptoms were entirely different.. Yep, we're both exhausted.. but she did keep some nausea medication down and ate 2 crackers,, and now Im working on getting some chicken noodle soup down her so she can take the meds she needs to before bed,, but she is soooooo grouchy,, Im trying hard NOT to take it personally but no matter what any of us talk about, she gets her knickers in a wad,, lol,, I sure hope tomorrow will be better!!! lol,thanks honey for all your concerns,,, AND,, how are you? How is your hubby doing and how many babies do you have right now?Sheena wrote: Jackie, could the antibiotics they have her on also be making her that sick? I sure hope she is doing better tonight, know you all must be so exhausted.. Love, Sheena Jackie on <redjaxjm> wrote: I spoke with her a

couple of min ago and she said she threw up last nite and again early this morning,, so I dont know.. Im trying to answer emails and then Im headed up there.. my mom needs me to go to the pharmacy for her too,, its always something liz,, lolelizabethnv1 <elizabethnv1earthlink (DOT) net> wrote: Hahaha I thought you'd get a kick out this . How is your daughter today ? Re: Silibinin Is a Potent Antiviral Agent in Patients with Chronic HCV Infection Not F I N A L L Y !!!! <elizabethnv1earthlink (DOT) net> wrote: Silibinin Is a Potent Antiviral Agent in Patients with Chronic HCV Infection Not Responding to Peginterferon/Ribavirin TherapyReported by Jules LevinDDW May 21, 2008, San Diego-Matthias Scherzer, Harald Hofer, Maximilian Schoeniger-Hekele, Petra Steindl-Munda, FerenciInternal Medicine 3, Dept of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, AustriaABSTRACT from program book.Results were reported at EASL, April 2008BACKROUND: Silibinin (SIL) is the main flavonoid extracted from milk thistle (Silibum marianum G.). Without a precise knowledge of its mode of action it can show beneficial effects

in various liver diseases. Recently it was shown that SIL inhibited viral replication in the Replicon® system (Gastroenterology 2007;132:1925). In the present study we investigated the antiviral activity of SIL in patients with chronic hepatitis C who did not respond to a previous course of standard PegIFN/RBV combination therapy. METHODS: 16 nonresponder (12 male; age: 49.9±9.7 (years, mean±SD); HCV-1: n=14; HCV-4: n=2; stage of fibrosis: F3/4: n=13, F1/2: n=3; 2 pts showed a > 2 log decline of viral load at wk 12 during the preceding therapy, none had an end of treatment response) were included. Since the efficacy of oral administration is limited by its low bioavailability treatment was started with 10mg/kg Silibinin (Legalon Sil®, Madaus, Köln) infused over 4 hrs for 7 days. On day 8 treatment was changed to 140 mg Silymarin (Legalon®, Madaus, Köln) TID per os in combination with 180µg/wk PegIFN

α-2a (PEGASYS®;Roche, Basel),1-1.2 g/d ribavirin (COPEGUS®; Roche, Basel). HCV-RNA was quantified by the TaqMan® assay (Roche Diagnostics) at baseline (BL), after 7 days of SIL iv. and every 2 wks on PegINF/RBV therapy, respectively. RESULTS: On iv. SIL-monotherapy all pts showed a substantial HCV RNA decline (BL: 6.68±5.69 day 8: 0.53±0.65 MIU/ml, (mean±SD, p<0.001) with a mean log decline of 1.32±0.55 within one wk. In parallel, ALT decreased from 162±133 to 118±107 U/l (mean±SD; p=0.004). In 3 patients viral kinetics were performed and showed a linear HCV RNA decline starting at day 3. Beside mild GI symptoms iv. SIL-monotherapy was well tolerated. After initiation of PegIFN/RBV the decrease of HCV-RNA was maintained (log drop: week 2: 1.17±0.67, week 4: 1.39±0.72; week 8: 1.47±0.86; all p<0.001 vs. BL). At the time of the meeting data amended 2 wk

regimes with iv. SIL at doses of 5 mg/kg, 10mg/kg and 15 mg/kg will be available. CONCLUSION: Intravenous SIL monotherapy is well tolerated and shows a substantial antiviral effect in chronic hepatitis C patients not responding to standard combination therapy. Thus, this drug may be useful for HCV treatment, especially in nonresponders or in combination with new antivirals. The antiviral effect of high dose iv SIL was not maintained on PegIFN/RBV therapy given together with a low dose oral preparation of SIL.EASL REPORT (5-20 mg dosing)SILIBININ IS A POTENT ANTIVIRAL AGENT IN CHRONIC HEPATITIS C NOT RESPONDING TO ANTIVIRAL COMBINATION THERAPY - (05/02/08)--------------------------------------------------------------------Jackie Jackie Jackie